
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is expected to benefit from favorable market conditions, continued demand for their innovative ICL products, and expansion into new international markets. Additionally, the recent launch of their EVO Viva ICL in Europe bodes well for future revenue growth. With positive momentum and a strong financial position, the company is well-positioned for long-term success.
Bears say
Staar Surgical is currently overvalued due to a combination of factors: 1) increased revenue estimates for FY'26 that rely heavily on China's rebound, despite management's cautious outlook and lack of formal guidance, 2) inflated valuation multiples compared to its peers and industry benchmarks, and 3) a lack of visibility into future numbers that could potentially impact long-term growth. Additionally, while the recent 1Q'26 results showed strong performance, there are concerns about the potential for a significant downturn in the overall market demand for Staar's ICL products, which account for the majority of its revenue.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares